Represent

Lobbying
Lobbying by GENZYME CORPORATION

Lobbying Relationship

Client

GENZYME CORPORATION

More records

Lobbying firm

GENZYME CORPORATION

More records

Medicare Part D coverage and patient access policies ESRD bundling and drug reimbursement issues HCPCS coding and reimbursement decisions Implementation of Patient Protection & Affordable Health Care Act (P.L. 111-148) and Implementation of Health Care and Education Reconciliation Act (P.L. 111-152) Least Costly Alternative (LCA) policy Changes regarding Medicare Part B and Average Sales Price Medicare secondary payor for ESRD services Extension of rebates on Medicare Part D drugs Performance measures for bone and mineral metabolism for ESRD program Implementation of American Taxpayer Relief Act of 2012 Access of ESRD patients to Medicare Advantage plans Chronic kidney care improvement
Implementation of Food and Drug Safety and Innovation Act (FDASIA) Issues and policies related to biosimilars exclusivity period Biosimilars FDA guidance Implementation of Patient Protection & Affordable Health Care Act (P.L. 111-148) and Implementation of Health Care and Education Reconciliation Act (P.L. 111-152) Issues and policies related to FDA oversight and management Issues and policies related to expanded access programs Issues and policies related to patient involvement with FDA decision making S. 204, Trickett Wendler Right to Try Act of 2017 H.R. 878, Right to Try Act of 2017
Implementation of Patient Protection & Affordable Health Care Act (P.L. 111-148) and Implementation of health Care and Education Reconciliation Act (P.L. 111-152) Excise tax for drugs and biologics Issues and policies related to Orphan Drug Tax Credit Implementation of American Taxpayer Relief Act of 2012 Issues and policies related to tax reform, including border adjustable tax Corporate tax inversion Legislation pertaining to the applicability of the ACA tax carve out for non-orphan designated drugs
Implementation of Patient Protection & Affordable Health Care Act (P.L. 111-148) and Implementation of Health Care and Education Reconcilation Act (P.L. 111-152) 340B issues and legislative reform proposals Issues related to importation of prescription drugs Health technology assessment of orphan and specialty drugs Implementation of the FDA Safety and Innovation Act (FDASIA) (P.L. 112-144) H.R. 1628, American Health Care Act of 2017 H.R. 1231, RACE for Children Act S. 456, RACE for Children Act Preserve Access to Affordable Generics Act H.R. 878, Right To Try Act of 2017 S. 204, Trickett Wendler Right To Try Act of 2017 Creating and restoring Equal Access to Equivalent Samples Act H.R. 314, Health Care Choice Act of 2017 S. 191, Patient Freedom Act of 2017 H.R. 184, Protect Medical Innovation Act of 2017 Regulation of innovative biologic products for neurodegenerative diseases Issues and policies related to implementation of Orphan Drug Act and orphan drug development Implementation of newborn screening programs Issues and policies related to biosimilars exclusivity period, including FDA guidance Issues and polices related to FDA oversight and management, including workforce authorities modernization Issues and policies related to expanded access programs Legislation pertaining to FDA priority review vouchers,generally Issues related to the value of prescription medicines, including affordability Drug shortage issues Issues related to health care transparency
Funding for FDA and NIH Issues and policies related to FY 2017 and FY 2018 appropriations and all applicable amendments Issues associated with budget reconciliation processes
Patent settlement legislation Preserve Access to Affordable Generics Act Creating and Restoring Equal Access to Equivalent Samples Act
Trade legislation and other trade authority Protection and promotion of 12 years exclusivity for biologics Protection and promotion of Orphan Drug Act market exclusivity

Duration: January 1, 2008 to March 31, 2017

General Issues: Medicare/Medicaid, Pharmacy, Taxation/Internal Revenue Code, Health Issues, Budget/Appropriations, Copyright/Patent/Trademark, Trade (Domestic & Foreign), Medical/Disease Research/Clinical Labs

Spending: about $17,375,154 (But it's complicated. Here's why.)

Agencies lobbied since 2008: U.S. Senate, House of Representatives, Centers For Medicare and Medicaid Services (CMS), Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), U.S. Senate,, Agency for Health Care Policy & Research, Treasury - Dept of, Executive Office of the President (EOP), Office of Management & Budget (OMB), Commerce - Dept of (DOC), Food & Drug Administration (FDA), Centers For Disease Control & Prevention (CDC), Health & Human Services - Dept of (HHS),

Bills mentioned

S.204: Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina...

Sponsor: Ron Johnson (R-Wis.)

H.R.878: Right to Try Act of 2017

Sponsor: Andy Biggs (R-Ariz.)

H.R.1628: American Health Care Act of 2017

Sponsor: Diane Black (R-Tenn.)

H.R.1231: RACE for Children Act

Sponsor: Michael McCaul (R-Texas)

S.456: RACE for Children Act

Sponsor: Michael Bennet (D-Colo.)

H.R.314: Health Care Choice Act of 2017

Sponsor: Marsha Blackburn (R-Tenn.)

S.191: Patient Freedom Act of 2017

Sponsor: Bill Cassidy (R-La.)

H.R.184: Protect Medical Innovation Act of 2018

Sponsor: Erik Paulsen (R-Minn.)

H.R.1416: Cancer Patient Protection Act of 2015

Sponsor: Renee Ellmers (R-N.C.)

H.R.6: 21st Century Cures Act

Sponsor: Fred Upton (R-Mich.)

S.506: A bill to amend part B of title XVIII of the Social Security Act to...

Sponsor: Pat Roberts (R-Kan.)

H.R.696: To amend part B of title XVIII of the Social Security Act to exclude...

Sponsor: Edward Whitfield (R-Ky.)

S.31: Medicare Prescription Drug Price Negotiation Act of 2015

Sponsor: Amy Klobuchar (D-Minn.)

H.R.1130: Chronic Kidney Disease Improvement in Research and Treatment Act of 2015

Sponsor: Tom Marino (R-Pa.)

S.598: Chronic Kidney Disease Improvement in Research and Treatment Act of 2015

Sponsor: Benjamin L. Cardin (D-Md.)

S.648: Medicare Formulary Improvement Act of 2015

Sponsor: Charles E. Grassley (R-Iowa)

H.R.2: Medicare Access and CHIP Reauthorization Act of 2015

Sponsor: Michael C. Burgess (R-Texas)

H.R.2570: Strengthening Medicare Advantage through Innovation and Transparency for...

Sponsor: Diane Black (R-Tenn.)

H.R.5122: To prohibit further action on the proposed rule regarding testing of...

Sponsor: Larry Bucshon (R-Ind.)

S.2912: Trickett Wendler Right to Try Act of 2016

Sponsor: Ron Johnson (R-Wis.)

H.R.3012: Right to Try Act of 2015

Sponsor: Matt Salmon (R-Ariz.)

H.R.880: American Research and Competitiveness Act of 2015

Sponsor: Kevin Brady (R-Texas)

S.537: COMPETE Act of 2015

Sponsor: Thomas R. Carper (D-Del.)

H.R.3678: Preserving Access to Orphan Drugs Act of 2015

Sponsor: Mike Kelly (R-Pa.)

H.R.3618: Orphan Drug Fairness Act

Sponsor: Leonard Lance (R-N.J.)

S.1906: Orphan Drug Fairness Act

Sponsor: Robert Menendez (D-N.J.)

S.122: Safe and Affordable Drugs from Canada Act of 2015

Sponsor: John McCain (R-Ariz.)

H.R.1376: Patient Choice Act of 2015

Sponsor: Morgan Griffith (R-Va.)

H.R.790: Compassionate Freedom of Choice Act of 2015

Sponsor: Morgan Griffith (R-Va.)

H.R.1600: Patients' Access to Treatments Act of 2015

Sponsor: David McKinley (R-W.Va.)

S.2055: Medical Countermeasure Innovation Act of 2016

Sponsor: Richard M. Burr (R-N.C.)

S.2512: Adding Zika Virus to the FDA Priority Review Voucher Program Act

Sponsor: Al Franken (D-Minn.)

S.2030: Advancing Targeted Therapies for Rare Diseases Act of 2016

Sponsor: Michael Bennet (D-Colo.)

S.849: Advancing Research for Neurological Diseases Act of 2016

Sponsor: Johnny Isakson (R-Ga.)

S.2700: FDA and NIH Workforce Authorities Modernization Act

Sponsor: Lamar Alexander (R-Tenn.)

H.R.909: Andrea Sloan CURE Act

Sponsor: Michael McCaul (R-Texas)

S.1421: Orphan Product Extensions Now Accelerating Cures and Treatments Act of 2015

Sponsor: Orrin G. Hatch (R-Utah)

H.R.971: Orphan Product Extensions Now Accelerating Cures and Treatments Act of 2015

Sponsor: Gus Bilirakis (R-Fla.)

S.320: Medical Innovation Act of 2015

Sponsor: Elizabeth Warren (D-Mass.)

H.R.744: Medical Innovation Act of 2015

Sponsor: Chris Van Hollen (D-Md.)

S.2615: Increasing Competition in Pharmaceuticals Act

Sponsor: Susan Collins (R-Maine)

H.R.1078: Food and Drug Administration Safety Over Sequestration Act of 2015

Sponsor: Leonard Lance (R-N.J.)

H.R.1531: Land Management Workforce Flexibility Act

Sponsor: Gerald E. Connolly (D-Va.)

S.1878: Advancing Hope Act of 2016

Sponsor: Bob Casey (D-Pa.)

S.289: American Cures Act

Sponsor: Richard J. Durbin (D-Ill.)

H.R.2104: American Cures Act

Sponsor: Anna G. Eshoo (D-Calif.)

S.2023: Prescription Drug Affordability Act of 2015

Sponsor: Bernard Sanders (ID-Vt.)

H.R.3299: Strengthening Public Health Emergency Response Act of 2016

Sponsor: Susan Brooks (R-Ind.)

S.2713: Advancing Precision Medicine Act of 2016

Sponsor: Lamar Alexander (R-Tenn.)

S.2745: Advancing NIH Strategic Planning and Representation in Medical Research Act

Sponsor: Susan Collins (R-Maine)

S.2742: Promoting Biomedical Research and Public Health for Patients Act

Sponsor: Lamar Alexander (R-Tenn.)

S.3239: RACE for Children Act

Sponsor: Michael Bennet (D-Colo.)

H.R.5858: RACE for Children Act

Sponsor: Michael McCaul (R-Texas)

S.2689: REGROW Act

Sponsor: Mark Steven Kirk (R-Ill.)

H.R.3762: To provide for reconciliation pursuant to section 2002 of the concurrent...

Sponsor: Tom Price (R-Ga.)

H.CON.RES.125: Establishing the congressional budget for the United States Government...

Sponsor: Tom Price (R-Ga.)

H.R.9: Innovation Act

Sponsor: Robert W. Goodlatte (R-Va.)

S.632: STRONG Patents Act of 2015

Sponsor: Christopher A. Coons (D-Del.)

S.1137: PATENT Act

Sponsor: Charles E. Grassley (R-Iowa)

S.2019: Preserve Access to Affordable Generics Act

Sponsor: Amy Klobuchar (D-Minn.)

S.3056: CREATES Act of 2016

Sponsor: Patrick J. Leahy (D-Vt.)

H.R.2029: Consolidated Appropriations Act, 2016

Sponsor: Charlie Dent (R-Pa.)

H.R.415: Stop Corporate Inversions Act of 2015

Sponsor: Sander M. Levin (D-Mich.)

S.198: Stop Corporate Inversions Act of 2015

Sponsor: Richard J. Durbin (D-Ill.)

H.R.2146: Defending Public Safety Employees' Retirement Act

Sponsor: Dave Reichert (R-Wash.)

S.995: Bipartisan Congressional Trade Priorities and Accountability Act of 2015

Sponsor: Orrin G. Hatch (R-Utah)

H.R.1890: Bipartisan Congressional Trade Priorities and Accountability Act of 2015

Sponsor: Paul D. Ryan (R-Wis.)

S.568: Trade Adjustment Assistance Act of 2015

Sponsor: Sherrod Brown (D-Ohio)

H.R.1088: Trade Adjustment Assistance Act of 2015

Sponsor: Adam Smith (D-Wash.)

H.R.413: To eliminate the 2-year delay in including oral-only ESRD-related drugs...

Sponsor: Peter Welch (D-Vt.)

S.77: Prescription Drug and Health Improvement Act of 2013

Sponsor: Al Franken (D-Minn.)

S.117: Medicare Prescription Drug Price Negotiation Act of 2013

Sponsor: Amy Klobuchar (D-Minn.)

H.R.800: To amend part B of title XVIII of the Social Security Act to exclude...

Sponsor: Edward Whitfield (R-Ky.)

H.R.1416: Cancer Patient Protection Act of 2013

Sponsor: Renee Ellmers (R-N.C.)

H.R.4302: Protecting Access to Medicare Act of 2014

Sponsor: Joe Pitts (R-Pa.)

H.R.4438: American Research and Competitiveness Act of 2014

Sponsor: Kevin Brady (R-Texas)

S.2715: COMPETE Act of 2014

Sponsor: Thomas R. Carper (D-Del.)

S.2786: Corporate Inverters Earnings Stripping Reform Act of 2014

Sponsor: Charles E. Schumer (D-N.Y.)

S.2704: No Federal Contracts for Corporate Deserters Act of 2014

Sponsor: Carl Levin (D-Mich.)

H.R.5278: No Federal Contracts for Corporate Deserters Act of 2014

Sponsor: Rosa DeLauro (D-Conn.)

H.R.4679: Stop Corporate Inversions Act of 2014

Sponsor: Sander M. Levin (D-Mich.)

S.2360: Stop Corporate Inversions Act of 2014

Sponsor: Carl Levin (D-Mich.)

S.1417: Newborn Screening Saves Lives Reauthorization Act of 2013

Sponsor: Kay Hagan (D-N.C.)

H.R.2315: Preserving Access to Orphan Drugs Act of 2013

Sponsor: Jim Gerlach (R-Pa.)

S.1128: Preserving Access to Orphan Drugs Act of 2013

Sponsor: Patrick J. Toomey (R-Pa.)

H.R.2090: Patient Choice Act of 2013

Sponsor: Morgan Griffith (R-Va.)

H.R.4475: Compassionate Freedom of Choice Act of 2014

Sponsor: Morgan Griffith (R-Va.)

H.R.1239: Accessing Medicare Therapies Act of 2013

Sponsor: Bill Cassidy (R-La.)

H.R.460: Patients' Access to Treatments Act of 2013

Sponsor: David McKinley (R-W.Va.)

H.R.3805: To provide for the redesignation of the Asia-Pacific Center for Security...

Sponsor: Colleen Hanabusa (D-Hawaii)

H.R.3116: MODDERN Cures Act of 2013

Sponsor: Leonard Lance (R-N.J.)

S.3004: Dormant Therapies Act of 2014

Sponsor: Orrin G. Hatch (R-Utah)

H.R.5771: Tax Increase Prevention Act of 2014

Sponsor: Dave Camp (R-Mich.)

H.R.5750: Orphan Product Extensions Now Accelerating Cures and Treatments Act of 2014

Sponsor: Gus Bilirakis (R-Fla.)

H.R.1516: Coast Guard Academy Opportunity Act

Sponsor: Bennie Thompson (D-Miss.)

S.1871: SGR Repeal and Medicare Beneficiary Access Act of 2013

Sponsor: Max Baucus (D-Mont.)

S.959: Pharmaceutical Quality, Security, and Accountability Act

Sponsor: Tom Harkin (D-Iowa)

S.957: Drug Supply Chain Security Act

Sponsor: Michael Bennet (D-Colo.)

H.R.1919: Safeguarding America's Pharmaceuticals Act of 2013

Sponsor: Robert E. Latta (R-Ohio)

H.R.1281: Newborn Screening Saves Lives Reauthorization Act of 2014

Sponsor: Lucille Roybal-Allard (D-Calif.)

H.R.2186: VALID Compounding Act

Sponsor: Edward J. Markey (D-Mass.)

H.J.RES.59: Continuing Appropriations Resolution, 2014

Sponsor: Harold Rogers (R-Ky.)

H.CON.RES.112: Establishing the budget for the United States Government for fiscal year...

Sponsor: Paul D. Ryan (R-Wis.)

H.R.6684: Spending Reduction Act of 2012

Sponsor: Eric Cantor (R-Va.)

H.R.8: American Taxpayer Relief Act of 2012

Sponsor: Dave Camp (R-Mich.)

H.R.6433: FDA User Fee Corrections Act of 2012

Sponsor: Fred Upton (R-Mich.)

S.810: Great Ape Protection and Cost Savings Act of 2011

Sponsor: Maria Cantwell (D-Wash.)

H.R.942: American Research and Competitiveness Act of 2011

Sponsor: Kevin Brady (R-Texas)

H.R.2674: 340B Program Improvement Act

Sponsor: Cathy McMorris Rodgers (R-Wash.)

H.R.5973: Agriculture, Rural Development, Food and Drug Administration, and...

Sponsor: Jack Kingston (R-Ga.)

S.2375: Agriculture, Rural Development, Food and Drug Administration, and...

Sponsor: Herb Kohl (D-Wis.)

H.J.RES.117: Continuing Appropriations Resolution, 2013

Sponsor: Harold Rogers (R-Ky.)

H.R.1249: Leahy-Smith America Invents Act

Sponsor: Lamar Smith (R-Texas)

S.23: America Invents Act

Sponsor: Patrick J. Leahy (D-Vt.)

H.R.2672: Preserving Access to Orphan Drugs Act of 2011

Sponsor: Jim Gerlach (R-Pa.)

S.1423: Preserving Access to Orphan Drugs Act of 2011

Sponsor: Patrick J. Toomey (R-Pa.)

S.606: Creating Hope Act of 2011

Sponsor: Bob Casey (D-Pa.)

H.R.3059: Creating Hope Act of 2011

Sponsor: Michael McCaul (R-Texas)

S.296: Preserving Access to Life-Saving Medications Act

Sponsor: Amy Klobuchar (D-Minn.)

H.R.2245: Preserving Access to Life-Saving Medications Act of 2011

Sponsor: Diana DeGette (D-Colo.)

H.R.1483: Drug Safety Enhancement Act of 2011

Sponsor: John D. Dingell (D-Mich.)

H.R.4132: FAST Act

Sponsor: Cliff Stearns (R-Fla.)

H.R.4156: EXPERRT Act of 2012

Sponsor: Edward J. Markey (D-Mass.)

H.R.2182: Generating Antibiotic Incentives Now Act of 2011

Sponsor: Phil Gingrey (R-Ga.)

S.1734: Generating Antibiotic Incentives Now Act of 2011

Sponsor: Richard Blumenthal (D-Conn.)

H.R.2055: Consolidated Appropriations Act, 2012

Sponsor: John Culberson (R-Texas)

H.R.3671: Consolidated Appropriations Act, 2012

Sponsor: Harold Rogers (R-Ky.)

H.R.3765: Temporary Payroll Tax Cut Continuation Act of 2011

Sponsor: Dave Camp (R-Mich.)

H.R.3630: Middle Class Tax Relief and Job Creation Act of 2012

Sponsor: Dave Camp (R-Mich.)

H.J.RES.95: Making further continuing appropriations for fiscal year 2012, and for...

Sponsor: Harold Rogers (R-Ky.)

H.J.RES.94: Making further continuing appropriations for fiscal year 2012, and for...

Sponsor: Harold Rogers (R-Ky.)

H.R.2608: Continuing Appropriations Act, 2012

Sponsor: Sam Graves (R-Mo.)

H.R.3743: Temporary Payroll Tax Cut Continuation Act of 2011

Sponsor: Sander M. Levin (D-Mich.)

H.R.2112: Consolidated and Further Continuing Appropriations Act, 2012

Sponsor: Jack Kingston (R-Ga.)

H.R.2482: Public Safety Spectrum and Wireless Innovation Act

Sponsor: John D. Dingell (D-Mich.)

S.515: Patent Reform Act of 2009

Sponsor: Patrick J. Leahy (D-Vt.)

H.R.1260: Patent Reform Act of 2009

Sponsor: John Conyers Jr. (D-Mich.)

S.610: Patent Reform Act of 2009

Sponsor: Jon Kyl (R-Ariz.)

S.3677: Financial Services and General Government Appropriations Act, 2011

Sponsor: Richard J. Durbin (D-Ill.)

H.R.444: 340B Program Improvement and Integrity Act of 2009

Sponsor: Bobby L. Rush (D-Ill.)

H.R.1699: Patient Access to Critical Lab Tests Act

Sponsor: Jason Altmire (D-Pa.)

H.R.1452: Medicare Clinical Diagnostic Laboratory Fee Schedule Modernization Act...

Sponsor: Bart Stupak (D-Mich.)

H.R.676: Expanded and Improved Medicare for All Act

Sponsor: John Conyers Jr. (D-Mich.)

S.11: A bill to restore the application of the 340B drug discount program to...

Sponsor: Scott Brown (R-Mass.)

H.R.4848: Tax Cut Job Creation Act of 2010

Sponsor: Don Young (R-Alaska)

H.R.1586: FAA Air Transportation Modernization and Safety Improvement Act

Sponsor: Charles B. Rangel (D-N.Y.)

H.R.4899: Supplemental Appropriations Act, 2010

Sponsor: David R. Obey (D-Wis.)

H.R.5712: Physician Payment and Therapy Relief Act of 2010

Sponsor: Sander M. Levin (D-Mich.)

H.R.3156: To amend the Internal Revenue Code of 1986 to provide a credit against...

Sponsor: Donald M. Payne (D-N.J.)

H.R.759: Food and Drug Administration Globalization Act of 2009

Sponsor: John D. Dingell (D-Mich.)

H.R.3081: Continuing Appropriations Act, 2011

Sponsor: Nita M. Lowey (D-N.Y.)

S.3686: Departments of Labor, Health and Human Services, and Education, and...

Sponsor: Tom Harkin (D-Iowa)

H.R.3082: Continuing Appropriations and Surface Transportation Extensions Act, 2011

Sponsor: Chet Edwards (D-Texas)

H.J.RES.105: Making further continuing appropriations for fiscal year 2011, and for...

Sponsor: David R. Obey (D-Wis.)

H.J.RES.101: Making further continuing appropriations for fiscal year 2011, and for...

Sponsor: David R. Obey (D-Wis.)

H.R.3962: Preservation of Access to Care for Medicare Beneficiaries and Pension...

Sponsor: John D. Dingell (D-Mich.)

H.R.3590: Patient Protection and Affordable Care Act

Sponsor: Charles B. Rangel (D-N.Y.)

H.R.4872: Health Care and Education Reconciliation Act of 2010

Sponsor: John M. Spratt Jr. (D-S.C.)

H.R.4851: Continuing Extension Act of 2010

Sponsor: Sander M. Levin (D-Mich.)

H.R.4213: Unemployment Compensation Extension Act of 2010

Sponsor: Charles B. Rangel (D-N.Y.)

H.R.2847: Hiring Incentives to Restore Employment Act

Sponsor: Alan B. Mollohan (D-W.Va.)

H.R.1548: Pathway for Biosimilars Act

Sponsor: Anna G. Eshoo (D-Calif.)

H.R.1427: Promoting Innovation and Access to Life-Saving Medicine Act

Sponsor: Henry A. Waxman (D-Calif.)

S.1679: Affordable Health Choices Act

Sponsor: Tom Harkin (D-Iowa)

H.R.1832: Medicare Prescription Drug Affordability Act of 2009

Sponsor: Robert Wexler (D-Fla.)

S.266: Medicare Prescription Drug Gap Reduction Act of 2009

Sponsor: Bill Nelson (D-Fla.)

S.301: Physician Payments Sunshine Act of 2009

Sponsor: Charles E. Grassley (R-Iowa)

S.1110: Medicare Payment Advisory Commission (MedPAC) Reform Act of 2009

Sponsor: John D. Rockefeller IV (D-W.Va.)

H.R.2502: Comparative Effectiveness Research Act of 2009

Sponsor: Kurt Schrader (D-Ore.)

S.1213: Patient-Centered Outcomes Research Act of 2009

Sponsor: Max Baucus (D-Mont.)

H.R.3200: America's Affordable Health Choices Act of 2009

Sponsor: John D. Dingell (D-Mich.)

S.726: Promoting Innovation and Access to Life-Saving Medicine Act

Sponsor: Charles E. Schumer (D-N.Y.)

H.R.1298: Pharmaceutical Market Access and Drug Safety Act of 2009

Sponsor: Marion Berry (D-Ark.)

S.525: Pharmaceutical Market Access and Drug Safety Act of 2009

Sponsor: Byron L. Dorgan (D-N.D.)

H.R.1: American Recovery and Reinvestment Act of 2009

Sponsor: David R. Obey (D-Wis.)

S.CON.RES.13: An original concurrent resolution setting forth the congressional budget...

Sponsor: Kent Conrad (D-N.D.)

H.R.3288: Consolidated Appropriations Act, 2010

Sponsor: John W. Olver (D-Mass.)

H.R.2997: Agriculture, Rural Development, Food and Drug Administration, and...

Sponsor: Rosa DeLauro (D-Conn.)

H.R.2892: Department of Homeland Security Appropriations Act, 2010

Sponsor: David E. Price (D-N.C.)

S.275: Children's Health Insurance Program Reauthorization Act of 2009

Sponsor: Max Baucus (D-Mont.)

H.R.2: Children's Health Insurance Program Reauthorization Act of 2009

Sponsor: Frank Pallone (D-N.J.)

S.350: American Recovery and Reinvestment Act of 2009

Sponsor: Max Baucus (D-Mont.)

H.CON.RES.85: Setting forth the congressional budget for the United States Government...

Sponsor: John M. Spratt Jr. (D-S.C.)

S.1145: Patent Reform Act of 2007

Sponsor: Patrick J. Leahy (D-Vt.)

H.R.1908: Patent Reform Act of 2007

Sponsor: Howard L. Berman (D-Calif.)

H.R.1038: Access to Life-Saving Medicine Act

Sponsor: Henry A. Waxman (D-Calif.)

H.R.1956: Patient Protection and Innovative Biologic Medicines Act of 2007

Sponsor: Jay Inslee (D-Wash.)

S.1505: Affordable Biologics for Consumers Act

Sponsor: Judd Gregg (R-N.H.)

S.1695: Biologics Price Competition and Innovation Act of 2007

Sponsor: Edward M. Kennedy (D-Mass.)

S.623: Access to Life-Saving Medicine Act

Sponsor: Charles E. Schumer (D-N.Y.)

S.3600: Patent Reform Act of 2008

Sponsor: Jon Kyl (R-Ariz.)

H.R.2606: 340B Program Improvement and Integrity Act of 2007

Sponsor: Bobby L. Rush (D-Ill.)

H.R.3162: Children's Health and Medicare Protection Act of 2007

Sponsor: John D. Dingell (D-Mich.)

H.R.4: Medicare Prescription Drug Price Negotiation Act of 2007

Sponsor: John D. Dingell (D-Mich.)

H.R.5480: Medicare Funding Warning Response Act of 2008

Sponsor: Steny H. Hoyer (D-Md.)

S.1376: 340B Program Improvement and Integrity Act of 2007

Sponsor: Jeff Bingaman (D-N.M.)

S.2029: Physician Payments Sunshine Act of 2007

Sponsor: Charles E. Grassley (R-Iowa)

S.2662: Medicare Funding Warning Response Act of 2008

Sponsor: Max Baucus (D-Mont.)

S.3: Medicare Prescription Drug Price Negotiation Act of 2007

Sponsor: Harry Reid (D-Nev.)

S.2099: Preserving Access to Laboratory Services Act of 2007

Sponsor: Ken Salazar (D-Colo.)

H.R.1321: Medicare Advanced Laboratory Diagnostics Act of 2007

Sponsor: Bobby L. Rush (D-Ill.)

S.691: Kidney Care Quality and Education Act of 2007

Sponsor: Kent Conrad (D-N.D.)

H.R.1193: Kidney Care Quality and Education Act of 2007

Sponsor: John Lewis (D-Ga.)

H.R.2184: Enhanced Health Care Value for All Act of 2007

Sponsor: Thomas H. Allen (D-Maine)

H.R.6331: Medicare Improvements for Patients and Providers Act of 2008

Sponsor: Charles B. Rangel (D-N.Y.)

S.3101: Medicare Improvements for Patients and Providers Act of 2008

Sponsor: Max Baucus (D-Mont.)

H.R.1472: Disabled Veterans Fairness Act

Sponsor: John Barrow (D-Ga.)

H.R.5629: Pathway for Biosimilars Act

Sponsor: Anna G. Eshoo (D-Calif.)

H.R.380: Pharmaceutical Market Access and Drug Safety Act of 2007

Sponsor: Rahm Emanuel (D-Ill.)

S.251: Pharmaceutical Market Access Act of 2007

Sponsor: David Vitter (R-La.)

S.242: Pharmaceutical Market Access and Drug Safety Act of 2007

Sponsor: Byron L. Dorgan (D-N.D.)

H.R.1561: Enhancing Drug Safety and Innovation Act of 2007

Sponsor: Henry A. Waxman (D-Calif.)

H.R.3610: Food and Drug Import Safety Act of 2007

Sponsor: John D. Dingell (D-Mich.)

S.4: Improving America's Security Act of 2007

Sponsor: Harry Reid (D-Nev.)

H.R.3453: Community Clinical Laboratory Fairness in Competition Act of 2007

Sponsor: Nydia M. Velázquez (D-N.Y.)

S.2404: Medicare Advanced Laboratory Diagnostics Act of 2007

Sponsor: Charles E. Schumer (D-N.Y.)

S.976: Genomics and Personalized Medicine Act of 2007

Sponsor: Barack Obama (D-Ill.)

S.736: Laboratory Test Improvement Act

Sponsor: Edward M. Kennedy (D-Mass.)

H.R.1424: A bill to provide authority for the Federal Government to purchase and...

Sponsor: Patrick J. Kennedy (D-R.I.)

H.R.548: To establish a Congressional Trade Office.

Sponsor: Peter A. DeFazio (D-Ore.)

Show All Mentioned Bills

Lobbyists

Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.

Lobbyist	Covered positions?
Sara Froelich	Vice President
Kay Holcombe	Senior Policy Advisor Senior Policy Advisory Vice President
Mary McGrane	Senior Vice President
Melissa Bartlett	n/a

Disclosures Filed

Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.

1st Quarter, 2017

Termination

GENZYME CORPORATION in-house lobbying effort was terminated on July 20, 2017 Original Filing: 300892425.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Implementation of Patient Protection & Affordable Health Care Act (P.L. 111-148) and Implementation of Health Care and Education Reconcilation Act (P.L. 111-152) 340B issues and legislative reform proposals Issues related to importation of prescription drugs Health technology assessment of orphan and specialty drugs Implementation of the FDA Safety and Innovation Act (FDASIA) (P.L. 112-144) H.R. 1628, American Health Care Act of 2017 H.R. 1231, RACE for Children Act S. 456, RACE for Children Act Preserve Access to Affordable Generics Act H.R. 878, Right To Try Act of 2017 S. 204, Trickett Wendler Right To Try Act of 2017 Creating and restoring Equal Access to Equivalent Samples Act H.R. 314, Health Care Choice Act of 2017 S. 191, Patient Freedom Act of 2017 H.R. 184, Protect Medical Innovation Act of 2017 Regulation of innovative biologic products for neurodegenerative diseases Issues and policies related to implementation of Orphan Drug Act and orphan drug development Implementation of newborn screening programs Issues and policies related to biosimilars exclusivity period, including FDA guidance Issues and polices related to FDA oversight and management, including workforce authorities modernization Issues and policies related to expanded access programs Legislation pertaining to FDA priority review vouchers,generally Issues related to the value of prescription medicines, including affordability Drug shortage issues Issues related to health care transparency

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2017

Q1 Report

In Q1, GENZYME CORPORATION had in-house lobbyists. The report was filed on April 21, 2017. Original Filing: 300878333.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2016

Q4 Report

In Q4, GENZYME CORPORATION had in-house lobbyists. The report was filed on Jan. 23, 2017. Original Filing: 300858226.xml

Lobbying Issues

Part D drug coverage and patient access issues and policy ESRD bundling and drug reimbursement issues HCPCS coding and reimbursement decisions Implementation of Patient Protection & Affordable Health Care Act (P.L. 111-148) and Implementation of Health Care and Education Reconciliation Act (P.L. 111-152) Least costly alternative (LCA) policy Changes re: Medicare Part B and Average Sales Price Medicare secondary payor for ESRD services Extension of rebates on Medicare Part D drugs Performance measures for bone and mineral metabolism for ESRD program Implementation of American Taxpayer Relief Act of 2012 H.R. 1416, Cancer Patient Protection Act of 2015 21st Century Cures/Innovation initiatives, including H.R. 6, 21st Century Cures Act S. 506, To amend Part B of title XVIII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare, and for other purposes H.R. 696, To amend part B of title XVIII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare, and for other purposes Medicaid drug rebate, drug coverage and patient access to therapies issues and policy S. 31, Medicare Prescription Drug Price Negotiation Act of 2015 H.R. 1130, Chronic Kidney Disease Improvement in Research and Treatment Act of 2015 S. 598, Chronic Kidney Disease Improvement in Research and Treatment Act of 2015 S. 648, Medicare Formulary Improvement Act of 2015 H.R. 2, Medicare Access and CHIP Reauthorization Act of 2015 H.R.2570, Strengthening Medicare Advantage through Innovation and Transparency for Seniors of 2015 H.R. 5122, To prohibit further action on the proposed rule regarding testing of Medicare Part B Prescription Drug Models

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Implementation of Patient Protection & Affordable Health Care Act (P.L. 111-148) and Implementation of Health Care and Education Reconciliation Act (P.L. 111-152) Excise tax for drugs and biologics Issues and policies related to Orphan Drug Tax Credit Implementation of American Taxpayer Relief Act of 2012 Issues and policies related to tax reform H.R. 880, American Research and Competitiveness Act of 2015 S. 537, Competitiveness and Opportunity by Modernizing and Permanently Extending the Tax Credit for Experimentation Act of 2015(COMPETE Act) Corporate tax inversions issues Legislation pertaining to the applicability of the ACA tax carve out for non-orphan drug designated drugs, generally, including H.R. 3678, Preserving Access to Orphan Drugs Act of 2015 H.R. 3618 and S. 1906, Orphan Drug Fairness Act Protecting Americans From Tax Hikes Act of 2015 (PATH)

Agencies Lobbied

Type of Issue

Lobbying Issues

Implementation of Patient Protection & Affordable Health Care Act (P.L. 111-148) and Implementation of Health Care and Education Reconciliation Act (P.L. 111-152) 340B issues and legislative reform proposals Issues related to importation of prescription drugs, including those contained in S. 122, Safe and Affordable Drugs from Canada Act of 2015 Health technology assessment of orphan drugs Sequestration of FDA user fees H.R. 1376, Patient Choice Act of 2015 H.R. 790, Compassionate Freedom of Choice Act of 2015 H.R. 1600, Patients' Access to Treatments Act of 2015 21st Century Cures/Innovation initiatives including H.R. 6, 21st Century Cures Act and the Innovation for Healthier Americans Initiative, including the following: S. 2055, The Medical Countermeasures Innovation Act of 2015; S. 2512, Adding Zika Virus to the FDA Priority Review Voucher Program Act; S. 2030, The Advancing Targeted Therapies for Rare Diseases Act of 2015; S. 849, Advancing Research for Neurological Diseases Act of 2015; S. 2700, FDA and NIH Workforces Authorities Modernization Act H.R. 909, Andrea Sloan CURE Act S. 1421 and H.R.971, Orphan Product Extensions Now Accelerating Cures and Treatments Act of 2015 Implementation of the FDA Safety and Innovation Act (FDASIA) (Pub. L. 112-144) Regulation of innovative biological products for neurodegenerative diseases Issues and policies related to implementation of Orphan Drug Act and orphan drug development S. 320, Medical Innovation Act H.R. 744, Medical Innovation Act S. 2615, Increasing Competition in Pharmaceuticals Act H.R. 1130, Chronic Kidney Disease Improvement in Research and Treatment Act of 2015 S. 598, Chronic Kidney Disease Improvement in Research and Treatment Act of 2015 H.R. 1078, Food and Drug Administration Safety Over Sequestration Act of 2015 H.R. 1531 and S.1878, Advancing Hope Act of 2015 Implementation of newborn screening programs Issues and policies related to biosimilars exclusivity period Issues and policies related to biosimilars FDA guidance Issues and policies related to FDA oversight and management Issues and policies related to expanded access programs Issues and policies related to patient involvement with FDA decision making S. 289 and H.R. 2104, American Cures Act Legislation pertaining to FDA priority review vouchers, generally Legislation pertaining to the applicability of the ACA tax carve out for non-orphan drug designated drugs, generally, including H.R. 3678, Preserving Access to Orphan Drugs Act of 2015 H.R. 3618 and S. 1906, Orphan Drug Fairness Act Issues related to the value of prescription medicines, generally, and including S. 2023, Prescription Drug Affordability Act of 2015 Drug shortage issues Issues related to health care transparency S. 2055, Medical Countermeasure Innovation Act of 2016 H.R. 3299, Strengthening Public Health Emergency Response Act S. 2700, FDA and NIH Workforce Authorities Modernization Act S. 2713, Advancing Precision Medicine Act of 2016 S. 2745, Advancing NIH Strategic Planning and Representation in Medical Research Act S. 2742, Promoting Biomedical Research and Public Health for Patients Act S. 3239, H.R. 5858, The RACE for Children Act S. 2689, The REGROW Act S. 1878, Advancing Hope Act of 2016

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2016

Q3 Report

In Q3, GENZYME CORPORATION had in-house lobbyists. The report was filed on Oct. 20, 2016. Original Filing: 300839645.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Implementation of Patient Protection & Affordable Health Care Act (P.L. 111-148) and Implementation of Health Care and Education Reconciliation Act (P.L. 111-152) 340B issues and legislative reform proposals Issues related to importation of prescription drugs, including those contained in S. 122, Safe and Affordable Drugs from Canada Act of 2015 Health technology assessment of orphan drugs Sequestration of FDA user fees H.R. 1376, Patient Choice Act of 2015 H.R. 790, Compassionate Freedom of Choice Act of 2015 H.R. 1600, Patients' Access to Treatments Act of 2015 21st Century Cures/Innovation initiatives including H.R. 6, 21st Century Cures Act and the Innovation for Healthier Americans Initiative, including the following: S. 2055, The Medical Countermeasures Innovation Act of 2015; S. 2512, Adding Zika Virus to the FDA Priority Review Voucher Program Act; S. 2030, The Advancing Targeted Therapies for Rare Diseases Act of 2015; S. 849, Advancing Research for Neurological Diseases Act of 2015; S. 2700, FDA and NIH Workfroces Authorities Modernization Act H.R. 909, Andrea Sloan CURE Act S. 1421 and H.R.971, Orphan Product Extensions Now Accelerating Cures and Treatments Act of 2015 Implementation of the FDA Safety and Innovation Act (FDASIA) (Pub. L. 112-144) Regulation of innovative biological products for neurodegenerative diseases Issues and policies related to implementation of Orphan Drug Act and orphan drug development S. 320, Medical Innovation Act H.R. 744, Medical Innovation Act S. 2615, Increasing Competition in Pharmaceuticals Act H.R. 1130, Chronic Kidney Disease Improvement in Research and Treatment Act of 2015 S. 598, Chronic Kidney Disease Improvement in Research and Treatment Act of 2015 H.R. 1078, Food and Drug Administration Safety Over Sequestration Act of 2015 H.R. 1531 and S.1878, Advancing Hope Act of 2015 Implementation of newborn screening programs Issues and policies related to biosimilars exclusivity period Issues and policies related to biosimilars FDA guidance Issues and policies related to FDA oversight and management Issues and policies related to expanded access programs Issues and policies related to patient involvement with FDA decision making S. 289 and H.R. 2104, American Cures Act Legislation pertaining to FDA priority review vouchers, generally Legislation pertaining to the applicability of the ACA tax carve out for non-orphan drug designated drugs, generally, including H.R. 3678, Preserving Access to Orphan Drugs Act of 2015 H.R. 3618 and S. 1906, Orphan Drug Fairness Act Issues related to the value of prescription medicines, generally, and including S. 2023, Prescription Drug Affordability Act of 2015 Drug shortage issues Issues related to health care transparency S. 2055, Medical Countermeasure Innovation Act of 2016 H.R. 3299, Strengthening Public Health Emergency Response Act S. 2700, FDA and NIH Workforce Authorities Modernization Act S. 2713, Advancing Precision Medicine Act of 2016 S. 2745, Advancing NIH Strategic Planning and Representation in Medical Research Act S. 2742, Promoting Biomedical Research and Public Health for Patients Act S. 3239, H.R. 5858, The RACE for Children Act S. 2689, The REGROW Act S. 1878, Advancing Hope Act of 2016

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2016

Q2 Report

In Q2, GENZYME CORPORATION had in-house lobbyists. The report was filed on July 20, 2016. Original Filing: 300821929.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Implementation of Patient Protection & Affordable Health Care Act (P.L. 111-148) and Implementation of Health Care and Education Reconciliation Act (P.L. 111-152) 340B issues and legislative reform proposals Issues related to importation of prescription drugs, including those contained in S. 122, Safe and Affordable Drugs from Canada Act of 2015 Health technology assessment of orphan drugs Sequestration of FDA user fees H.R. 1376, Patient Choice Act of 2015 H.R. 790, Compassionate Freedom of Choice Act of 2015 H.R. 1600, Patients' Access to Treatments Act of 2015 21st Century Cures/Innovation initiatives including H.R. 6, 21st Century Cures Act and the Innovation for Healthier Americans Initiative, including the following: S. 2055, The Medical Countermeasures Innovation Act of 2015; S. 2512, Adding Zika Virus to the FDA Priority Review Voucher Program Act; S. 2030, The Advancing Targeted Therapies for Rare Diseases Act of 2015; S. 849, Advancing Research for Neurological Diseases Act of 2015; S. 2700, FDA and NIH Workfroces Authorities Modernization Act H.R. 909, Andrea Sloan CURE Act S. 1421 and H.R.971, Orphan Product Extensions Now Accelerating Cures and Treatments Act of 2015 Implementation of the FDA Safety and Innovation Act (FDASIA) (Pub. L. 112-144) Regulation of innovative biological products for neurodegenerative diseases Issues and policies related to implementation of Orphan Drug Act and orphan drug development S. 320, Medical Innovation Act H.R. 744, Medical Innovation Act S. 2615, Increasing Competition in Pharmaceuticals Act H.R. 1130, Chronic Kidney Disease Improvement in Research and Treatment Act of 2015 S. 598, Chronic Kidney Disease Improvement in Research and Treatment Act of 2015 H.R. 1078, Food and Drug Administration Safety Over Sequestration Act of 2015 H.R. 1531 and S.1878, Advancing Hope Act of 2015 Implementation of newborn screening programs Issues and policies related to biosimilars exclusivity period Issues and policies related to biosimilars FDA guidance Issues and policies related to FDA oversight and management Issues and policies related to expanded access programs Issues and policies related to patient involvement with FDA decision making S. 289 and H.R. 2104, American Cures Act Legislation pertaining to FDA priority review vouchers, generally Legislation pertaining to the applicability of the ACA tax carve out for non-orphan drug designated drugs, generally, including H.R. 3678, Preserving Access to Orphan Drugs Act of 2015 H.R. 3618 and S. 1906, Orphan Drug Fairness Act Issues related to the value of prescription medicines, generally, and including S. 2023, Prescription Drug Affordability Act of 2015 Drug shortage issues Issues related to health care transparency S. 2055, Medical Countermeasure Innovation Act of 2016 H.R. 3299, Strengthening Public Health Emergency Response Act S. 2700, FDA and NIH Workforce Authorities Modernization Act S. 2713, Advancing Precision Medicine Act of 2016 S. 2745, Advancing NIH Strategic Planning and Representation in Medical Research Act S. 2742, Promoting Biomedical Research and Public Health for Patients Act S. 3239, H.R. 5858, The RACE for Children Act S. 2689, The REGROW Act

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2016

Q1 Report

In Q1, GENZYME CORPORATION had in-house lobbyists. The report was filed on April 20, 2016. Original Filing: 300802120.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Implementation of Patient Protection & Affordable Health Care Act (P.L. 111-148) and Implementation of Health Care and Education Reconciliation Act (P.L. 111-152) 340B issues and legislative reform proposals Issues related to importation of prescription drugs, including those contained in S. 122, Safe and Affordable Drugs from Canada Act of 2015 Health technology assessment of orphan drugs Sequestration of FDA user fees H.R. 1376, Patient Choice Act of 2015 H.R. 790, Compassionate Freedom of Choice Act of 2015 H.R. 1600, Patients' Access to Treatments Act of 2015 21st Century Cures/Innovation initiatives including H.R. 6, 21st Century Cures Act and the Innovation for Healthier Americans Initiative, including the following: S. 2055, The Medical Countermeasures Innovation Act of 2015; S. 2512, Adding Zika Virus to the FDA Priority Review Voucher Program Act; S. 2030, The Advancing Targeted Therapies for Rare Diseases Act of 2015; S. 849, Advancing Research for Neurological Diseases Act of 2015; S. 2700, FDA and NIH Workfroces Authorities Modernization Act H.R. 909, Andrea Sloan CURE Act S. 1421 and H.R.971, Orphan Product Extensions Now Accelerating Cures and Treatments Act of 2015 Implementation of the FDA Safety and Innovation Act (FDASIA) (Pub. L. 112-144) Regulation of innovative biological products for neurodegenerative diseases Issues and policies related to implementation of Orphan Drug Act and orphan drug development S. 320, Medical Innovation Act H.R. 744, Medical Innovation Act S. 2615, Increasing Competition in Pharmaceuticals Act H.R. 1130, Chronic Kidney Disease Improvement in Research and Treatment Act of 2015 S. 598, Chronic Kidney Disease Improvement in Research and Treatment Act of 2015 H.R. 1078, Food and Drug Administration Safety Over Sequestration Act of 2015 H.R. 1531 and S.1878, Advancing Hope Act of 2015 Implementation of newborn screening programs Issues and policies related to biosimilars exclusivity period Issues and policies related to biosimilars FDA guidance Issues and policies related to FDA oversight and management Issues and policies related to expanded access programs Issues and policies related to patient involvement with FDA decision making S. 289 and H.R. 2104, American Cures Act Legislation pertaining to FDA priority review vouchers, generally Legislation pertaining to the applicability of the ACA tax carve out for non-orphan drug designated drugs, generally, including H.R. 3678, Preserving Access to Orphan Drugs Act of 2015 H.R. 3618 and S. 1906, Orphan Drug Fairness Act Issues related to the value of prescription medicines, generally, and including S. 2023, Prescription Drug Affordability Act of 2015 Drug shortage issues Issues related to health care transparency

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2015

Q4 Report

In Q4, GENZYME CORPORATION had in-house lobbyists. The report was filed on Jan. 20, 2016. Original Filing: 300782807.xml

Lobbying Issues

Part D drug coverage and patient access issues and policy ESRD bundling and drug reimbursement issues HCPCS coding and reimbursement decisions Implementation of Patient Protection & Affordable Health Care Act (P.L. 111-148) and Implementation of Health Care and Education Reconciliation Act (P.L. 111-152) Least costly alternative policy Changes re: Medicare Part B and Average Sales Price Medicare secondary payor for ESRD services Extension of rebates on Medicare Part D drugs Performance measures for bone and mineral metabolism for ESRD program Implementation of American Taxpayer Relief Act of 2012 H.R. 1416, Cancer Patient Protection Act of 2015 21st Century Cures/Innovation initiatives, including H.R. 6, 21st Century Cures Act S. 506, To amend Part B of title XVIII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare, and for other purposes H.R. 696, To amend part B of title XVIII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare, and for other purposes Medicaid drug rebate, drug coverage and patient access to therapies issues and policy S. 31, Medicare Prescription Drug Price Negotiation Act of 2015 H.R. 1130, Chronic Kidney Disease Improvement in Research and Treatment Act of 2015 S. 598, Chronic Kidney Disease Improvement in Research and Treatment Act of 2015 S. 648, Medicare Formulary Improvement Act of 2015 H.R. 2, Medicare Access and CHIP Reauthorization Act of 2015 H.R.2570, Strengthening Medicare Advantage through Innovation and Transparency for Seniors of 2015

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Implementation of Patient Protection & Affordable Health Care Act (P.L. 111-148) and Implementation of Health Care and Education Reconciliation Act (P.L. 111-152) Excise tax for drugs and biologics Extension of R& D tax credit Issues and policies related to Orphan Drug Tax Credit Implementation of American Taxpayer Relief Act of 2012 Issues and policies related to tax reform H.R. 880, American Research and Competitiveness Act of 2015 S. 537, Competitiveness and Opportunity by Modernizing and Permanently Extending the Tax Credit for Experimentation Act of 2015(COMPETE Act) Corporate tax inversions issues Legislation pertaining to the applicability of the ACA tax carve out for non-orphan drug designated drugs, generally, including H.R. 3678, Preserving Access to Orphan Drugs Act of 2015 H.R. 3618 and S. 1906, Orphan Drug Fairness Act Protecting Americans From Tax Hikes Act of 2015 (PATH)

Agencies Lobbied

Type of Issue

Lobbying Issues

Implementation of Patient Protection & Affordable Health Care Act (P.L. 111-148) and Implementation of Health Care and Education Reconciliation Act (P.L. 111-152) 340B issues and legislative reform proposals Issues related to importation of prescription drugs, including those contained in S. 122, Safe and Affordable Drugs from Canada Act of 2015 Health technology assessment of orphan drugs Sequestration of FDA user fees H.R. 1376, Patient Choice Act of 2015 H.R. 790, Compassionate Freedom of Choice Act of 2015 H.R. 1600, Patients' Access to Treatments Act of 2015 21st Century Cures/Innovation initiatives including H.R. 6, 21st Century Cures Act and the Innovation for Healthier Americans Initiative H.R. 909, Andrea Sloan CURE Act S. 1421 and H.R.971, Orphan Product Extensions Now Accelerating Cures and Treatments Act of 2015 Implementation of the FDA Safety and Innovation Act (FDASIA) (Pub. L. 112-144) Regulation of innovative biological products for neurodegenerative diseases Issues and policies related to implementation of Orphan Drug Act and orphan drug development S. 320, Medical Innovation Act H.R. 744, Medical Innovation Act H.R. 1130, Chronic Kidney Disease Improvement in Research and Treatment Act of 2015 S. 598, Chronic Kidney Disease Improvement in Research and Treatment Act of 2015 H.R. 1078, Food and Drug Administration Safety Over Sequestration Act of 2015 H.R. 1531 and S.1878, Advancing Hope Act of 2015 Implementation of newborn screening programs Issues and policies related to biosimilars exclusivity period Issues and policies related to biosimilars FDA guidance Issues and policies related to FDA oversight and management Issues and policies related to expanded access programs Issues and policies related to patient involvement with FDA decision making S. 289 and H.R. 2104, American Cures Act Legislation pertaining to FDA priority review vouchers, generally Legislation pertaining to the applicability of the ACA tax carve out for non-orphan drug designated drugs, generally, including H.R. 3678, Preserving Access to Orphan Drugs Act of 2015 H.R. 3618 and S. 1906, Orphan Drug Fairness Act Issues related to the value of prescription medicines, generally, and including S. 2023, Prescription Drug Affordability Act of 2015 Drug shortage issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2015

Q3 Report

In Q3, GENZYME CORPORATION had in-house lobbyists. The report was filed on Oct. 20, 2015. Original Filing: 300764628.xml

Lobbying Issues

Part D Drug Coverage and Patient Access ESRD "Bundling Issues" and ESRD Drug Reimbursement Issues HCPCS Coding and Reimbursement Decisions Implementation of P.L. 111-148, Patient Protection & Affordable Health Care Act and Implementation of Health Care and Education Reconciliation Act (P.L. 111-152) Least Costly Alternative Policy Changes re: Medicare Part B and Average Sales Price Medicare Secondary Payor for ESRD Services Extension of Rebates on Medicare Part D Drugs Performance Measures for Bone and Mineral Metabolism for ESRD Program Implementation of American Taxpayer Relief Act of 2012 H.R. 1416, Cancer Patient Protection Act of 2015 21st Century Cures Initiatives, H.R.6, 21st Century Cures Act S. 506, To amend part B of title XVIII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare, and for other purposes H.R. 696, To amend part B of title XVIII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare, and for other purposes Medicaid drug rebate, drug coverage and patient access to therapies issues S. 31, Medicare Prescription Drug Price Negotiation Act of 2015 H.R. 1130, Chronic Kidney Disease Improvement in Research and Treatment Act of 2015 S. 598, Chronic Kidney Disease Improvement in Research and Treatment Act of 2015 S. 648, Medicare Formulary Improvement Act of 2015 H.R. 2, Medicare Access and CHIP Reauthorization Act of 2015 H.R.2570, Strengthening Medicare Advantage through Innovation and Transparency for Seniors of 2015

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Implementation of P.L. 111-148, Patient Protection & Affordable Health Care Act and Implementation of Health Care and Education Reconciliation Act (P.L. 111-152) Excise Tax for Drugs and Biologics Extension of R& D Tax Credit Orphan Drug Tax Credit Implementation of American Taxpayer Relief Act of 2012 Tax Reform H.R. 880, American Research and Competitiveness Act of 2015 S. 537, Competitiveness and Opportunity by Modernizing and Permanently Extending the Tax Credit for Experimentation Act of 2015(COMPETE Act) Corporate Tax Inversions Issues H.R.415, Stop Corporate Inversions Act of 2015 S. 198, Stop Corporate Inversions Act of 2015 Legislation pertaining to the applicability of the ACA tax carve out for non-orphan drug designated drugs, generally, including H.R. 3678, Preserving Access to Orphan Drugs Act of 2015 H.R. 3618 and S. 1906, Orphan Drug Fairness Act

Agencies Lobbied

Type of Issue

Lobbying Issues

Implementation of P.L. 111-148, Patient Protection & Affordable Health Care Act and Implementation of Health Care and Education Reconciliation Act (P.L. 111-152) 340B Issues and Legislative Reform Proposals Drug Shortage Issues Health Technology Assessment of Orphan Drugs Sequestration of FDA User Fees H.R. 1376, Patient Choice Act of 2015 H.R. 790, Compassionate Freedom of Choice Act of 2015 H.R. 1600, Patients' Access to Treatments Act of 2015 21st Century Cures Initiative including H.R.6, 21st Century Cures Act and the Innovation for Healthier Americans Initiative H.R. 909, Andrea Sloan CURE Act S. 1421 and H.R.971, Orphan Product Extensions Now Accelerating Cures and Treatments Act of 2015 Implementation of the FDA Safety and Innovation Act (FDASIA) (Pub. L. 112-144) Regulation of innovative biological products for neurodegenerative diseases. Implementation of Orphan Drug Act and Orphan Drug Development S. 122, Safe and Affordable Drugs from Canada Act of 2015 S. 320, Medical Innovation Act H.R. 744, Medical Innovation Act H.R. 1130, Chronic Kidney Disease Improvement in Research and Treatment Act of 2015 S. 598, Chronic Kidney Disease Improvement in Research and Treatment Act of 2015 H.R. 1078, Food and Drug Administration Safety Over Sequestration Act of 2015 H.R. 1531 and S.1878, Advancing Hope Act of 2015 Implementation of Newborn Screening Programs Biosimilars Exclusivity Period Biosimilars FDA Guidance FDA Oversight and Management Expanded Access Programs Patient Involvement with FDA Decision Making S. 289 and H.R. 2104, American Cures Act Legislation pertaining to priority review vouchers, generally Legislation pertaining to the applicability of the ACA tax carve out for non-orphan drug designated drugs, generally, including H.R. 3678, Preserving Access to Orphan Drugs Act of 2015 H.R. 3618 and S. 1906, Orphan Drug Fairness Act Issues related to the value of prescription medicines, generally, and including S. 2023,Prescription Drug Affordability Act of 2015

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2015

Q2 Report

In Q2, GENZYME CORPORATION had in-house lobbyists. The report was filed on July 20, 2015. Original Filing: 300745141.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Implementation of P.L. 111-148, Patient Protection & Affordable Health Care Act and Implementation of Health Care and Education Reconciliation Act (P.L. 111-152) 340B Issues and Legislative Reform Proposals Drug Shortage Issues Health Technology Assessment of Orphan Drugs Sequestration of FDA User Fees H.R. 1376, Patient Choice Act of 2015 H.R. 790, Compassionate Freedom of Choice Act of 2015 H.R. 1600, Patients' Access to Treatments Act of 2015 21st Century Cures Initiative including H.R.6, 21st Century Cures Act H.R. 909, Andrea Sloan CURE Act S. 1421 and H.R.971, Orphan Product Extensions Now Accelerating Cures and Treatments Act of 2015 Implementation of the FDA Safety and Innovation Act (FDASIA) (Pub. L. 112-144) Regulation of innovative biological products for neurodegenerative diseases. Implementation of Orphan Drug Act and Orphan Drug Development S. 122, Safe and Affordable Drugs from Canada Act of 2015 S. 320, Medical Innovation Act H.R. 744, Medical Innovation Act H.R. 1130, Chronic Kidney Disease Improvement in Research and Treatment Act of 2015 S. 598, Chronic Kidney Disease Improvement in Research and Treatment Act of 2015 H.R. 1078, Food and Drug Administration Safety Over Sequestration Act of 2015 H.R. 1531, Advancing Hope Act of 2015 Implementation of Newborn Screening Programs Biosimilars Exclusivity Period Biosimilars FDA Guidance FDA Oversight and Management Expanded Access Programs Patient Involvement with FDA Decision Making S. 289 and H.R. 2104, American Cures Act

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2015

Q1 Report

In Q1, GENZYME CORPORATION had in-house lobbyists. The report was filed on April 20, 2015. Original Filing: 300727138.xml

Lobbying Issues

Part D Drug Coverage and Patient Access ESRD "Bundling Issues" and ESRD Drug Reimbursement Issues HCPCS Coding and Reimbursement Decisions Implementation of P.L. 111-148, Patient Protection & Affordable Health Care Act and Implementation of Health Care and Education Reconciliation Act (P.L. 111-152) Least Costly Alternative Policy Changes re: Medicare Part B and Average Sales Price Medicare Secondary Payor for ESRD Services Extension of Rebates on Medicare Part D Drugs Performance Measures for Bone and Mineral Metabolism for ESRD Program Implementation of American Taxpayer Relief Act of 2012 H.R. 1416, Cancer Patient Protection Act of 2015 21st Century Cures Initiatives S. 506, To amend part B of title XVIII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare, and for other purposes H.R. 696, To amend part B of title XVIII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare, and for other purposes Medicaid drug rebate, drug coverage and patient access to therapies issues S. 31, Medicare Prescription Drug Price Negotiation Act of 2015 H.R. 1130, Chronic Kidney Disease Improvement in Research and Treatment Act of 2015 S. 598, Chronic Kidney Disease Improvement in Research and Treatment Act of 2015 S. 648, Medicare Formulary Improvement Act of 2015 HR 2, Medicare Access and CHIP Reauthorization Act of 2015

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Implementation of P.L. 111-148, Patient Protection & Affordable Health Care Act and Implementation of Health Care and Education Reconciliation Act (P.L. 111-152) 340B Issues Drug Shortage Issues Health Technology Assessment of Orphan Drugs Sequestration of FDA User Fees H.R. 1376, Patient Choice Act of 2015 H.R. 790, Compassionate Freedom of Choice Act of 2015 H.R. 1600, Patients' Access to Treatments Act of 2015 21st Century Cures Initiative H.R. 909, Andrea Sloan CURE Act H.R.971, Orphan Product Extensions Now Accelerating Cures and Treatments Act of 2015 Implementation of the FDA Safety and Innovation Act (FDASIA) (Pub. L. 112-144) Regulation of innovative biological products for neurodegenerative diseases. Implementation of Orphan Drug Act and Orphan Drug Development S. 122, Safe and Affordable Drugs from Canada Act of 2015 S. 320, Medical Innovation Act H.R. 744, Medical Innovation Act H.R. 1130, Chronic Kidney Disease Improvement in Research and Treatment Act of 2015 S. 598, Chronic Kidney Disease Improvement in Research and Treatment Act of 2015 H.R. 1078, Food and Drug Administration Safety Over Sequestration Act of 2015 H.R. 1531, Advancing Hope Act of 2015 Implementation of Newborn Screening Programs Biosimilars Exclusivity Period Biosimilars FDA Guidance FDA Oversight and Management Expanded Access Programs Patient Involvement with FDA Decision Making H.R. 1078, Food and Drug Administration Safety Over Sequestration Act of 2015

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2014

Q4 Report

In Q4, GENZYME CORPORATION had in-house lobbyists. The report was filed on Jan. 20, 2015. Original Filing: 300706945.xml

Lobbying Issues

ESRD "Bundling Issues" and ESRD Drug Reimbursement Issues HCPCS Coding and Reimbursement Decisions Implementation of P.L. 111-148, Patient Protection & Affordable Health Care Act Least Costly Alternative PolicyChanges re: Medicare Part B and Average Sales Price Medicare Secondary Payor for ESRD Services Extension of Rebates on Medicare Part D Drugs Performance Measures for Bone and Mineral Metabolism for ESRD Program Implementation of American Taxpayer Relief Act of 2012 H.R. 413, to eliminate two-year delay including oral-only ESRD-related drugs in the Medicate ESRD prospective payment system S. 77, Prescription Drug and Health Improvement Act of 2013 S. 117, Medicare Prescription Drug Price Negotiation Act of 2013 H.R. 800, to exclude prompt pay discounts from the average sales price for drugs and biologics under Medicare Part B H.R. 1416, Cancer Patient Protection Act of 2013 H.R. 4302, Protecting Access to Medicare Act of 2014 21st Century Cures Initiatives

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Implementation of P.L. 111-148, Patient Protection & Affordable Health Care Act 340B Issues Drug Shortage Issues Health Technology Assessment of Orphan DrugsH.R. 1281, Newborn Screening Saves Lives Reauthorization Act of 2013 S. 1417, Newborn Screening Saves Lives Reauthorization Act of 2013 Sequestration of FDA User Fees H.R. 2315, Preserving Access to Orphan Drugs Act of 2013 S. 1128, Preserving Access to Orphan Drugs Act of 2013 H.R. 2090, Patient Choice Act of 2013 H.R. 4475, Compassionate Freedom of Choice Act of 2014 H.R. 1239, Accessing Medicare Therapies Act of 2013 H.R. 460, Patients' Access to Treatments Act of 2013 21st Century Cures Initiatives H.R. 3805, Andrea Sloan CURE Act H.R. 3116, MODDERN Cures Act of 2013 S. 3004, Dormant Therapies Act of 2014 H.R. 5771, To amend the Internal Revenue Code of 1986 to extend certain expiring provisions and make technical corrections, to amend the Internal Revenue Code of 1986 to provide for the tax treatment of ABLE accounts established under State programs for the care of family members with disabilities, and for other purposes. H.R. 5750, Orphan Product Extensions Now Accelerating Cures and Treatments Act of 2014

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2014

Q3 Report

In Q3, GENZYME CORPORATION had in-house lobbyists. The report was filed on Oct. 20, 2014. Original Filing: 300688046.xml

Lobbying Issues

ESRD "Bundling Issues" and ESRD Drug Reimbursement Issues HCPCS Coding Decisions Implementation of P.L. 111-148, Patient Protection & Affordable Health Care Act Least Costly Alternative PolicyChanges re: Medicare Part B and Average Sales Price Medicare Secondary Payor for ESRD Services Extension of Rebates on Medicare Part D Drugs Performance Measures for Bone and Mineral Metabolism for ESRD Program 340B Issues Implementation of American Taxpayer Relief Act of 2012 H.R. 413, to eliminate two-year delay including oral-only ESRD-related drugs in the Medicate ESRD prospective payment system S. 77, Prescription Drug and Health Improvement Act of 2013 S. 117, Medicare Prescription Drug Price Negotiation Act of 2013 H.R. 800, to exclude prompt pay discounts from the average sales price for drugs and biologics under Medicare Part B H.R. 1516, Cancer Patient Protection Act of 2013 H.R. 4302, Protecting Access to Medicare Act of 2014 21st Century Cures Initiatives

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2014

Q2 Report

In Q2, GENZYME CORPORATION had in-house lobbyists. The report was filed on July 21, 2014. Original Filing: 300668513.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2014

Q1 Report

In Q1, GENZYME CORPORATION had in-house lobbyists. The report was filed on April 21, 2014. Original Filing: 300648216.xml

Lobbying Issues

ESRD "Bundling Issues" and ESRD Drug Reimbursement Issues HCPCS Coding Decisions Implementation of P.L. 111-148, Patient Protection & Affordable Health Care Act Least Costly Alternative PolicyChanges re: Medicare Part B and Average Sales Price Medicare Secondary Payor for ESRD Services Extension of Rebates on Medicare Part D Drugs Performance Measures for Bone and Mineral Metabolism for ESRD Program 340B Issues Implementation of American Taxpayer Relief Act of 2012 H.R. 413, to eliminate two-year delay including oral-only ESRD-related drugs in the Medicate ESRD prospective payment system S. 77, Prescription Drug and Health Improvement Act of 2013 S. 117, Medicare Prescription Drug Price Negotiation Act of 2013 H.R. 800, to exclude prompt pay discounts from the average sales price for drugs and biologics under Medicare Part B H.R. 1516, Cancer Patient Protection Act of 2013 S. 1871, Sustainable Growth Rate (SGR) Repeal and Medicare Beneficiary Access Act of 2013 H.R. 4302, Protecting Access to Medicare Act of 2014

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2013

Q4 Report

In Q4, GENZYME CORPORATION had in-house lobbyists. The report was filed on Jan. 20, 2014. Original Filing: 300621867.xml

Lobbying Issues

ESRD "Bundling Issues" and ESRD Drug Reimbursement Issues HCPCS Coding Decisions Implementation of P.L. 111-148, Patient Protection & Affordable Health Care Act Least Costly Alternative PolicyChanges re: Medicare Part B and Average Sales Price Medicare Secondary Payor for ESRD Services Extension of Rebates on Medicare Part D Drugs Performance Measures for Bone and Mineral Metabolism for ESRD Program 340B Issues Implementation of American Taxpayer Relief Act of 2012 H.R. 413, to eliminate two-year delay including oral-only ESRD-related drugs in the Medicate ESRD prospective payment system S. 77, Prescription Drug and Health Improvement Act of 2013 S. 117, Medicare Prescription Drug Price Negotiation Act of 2013 H.R. 800, to exclude prompt pay discounts from the average sales price for drugs and biologics under Medicare Part B H.R. 1516, Cancer Patient Protection Act of 2013 S. 1871, Sustainable Growth Rate (SGR) Repeal and Medicare Beneficiary Access Act of 2013

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2013

Q3 Report

In Q3, GENZYME CORPORATION had in-house lobbyists. The report was filed on Oct. 21, 2013. Original Filing: 300606063.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2013

Q2 Report

In Q2, GENZYME CORPORATION had in-house lobbyists. The report was filed on July 22, 2013. Original Filing: 300585634.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2013

Q1 Report

In Q1, GENZYME CORPORATION had in-house lobbyists. The report was filed on April 22, 2013. Original Filing: 300563330.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2012

Q4 Report

In Q4, GENZYME CORPORATION had in-house lobbyists. The report was filed on Jan. 22, 2013. Original Filing: 300541908.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2012

Q3 Report

In Q3, GENZYME CORPORATION had in-house lobbyists. The report was filed on Oct. 22, 2012. Original Filing: 300520938.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

S.606/H.R. 3059 - Creating Hope Act of 2011 Food and Drug Administration Safety and Innovation Act Implementation S. 296/H.R. 2245, Preserving Access to Life-Saving Medications Act H.R. 1483, Drug Safety Enhancement ActH.R. 3737, ULTRA (Unlocking Lifesaving Treatments for Rare Diseases) Act H.R. 4132, FAST (Faster Access to Specialized Treatments) Act Amendments to FDA Accelerated Approval Requirements H.R. 4156, EXPERRT (Expanding and Promoting Expertise in Review of Rare Treatments) Act H.R. 2182, GAIN (Generating Antibiotic Incentives Now) Act S. 1734, Generating Antibiotic Incentives Now Act Biosimilars User Fees Biosimilars Exclusivity Period in Administration's Budget Proposals Report on Innovation/FDA by President's Council of Advisors on Science and Technology (CPAST)

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2012

Q2 Report

In Q2, GENZYME CORPORATION had in-house lobbyists. The report was filed on July 19, 2012. Original Filing: 300492789.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2012

Q1 Report

In Q1, GENZYME CORPORATION had in-house lobbyists. The report was filed on April 20, 2012. Original Filing: 300474440.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2011

Q4 Report

In Q4, GENZYME CORPORATION had in-house lobbyists. The report was filed on Jan. 20, 2012. Original Filing: 300451847.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2011

Q3 Report

In Q3, GENZYME CORPORATION had in-house lobbyists. The report was filed on Oct. 19, 2011. Original Filing: 300421395.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2011

Q2 Report

In Q2, GENZYME CORPORATION had in-house lobbyists. The report was filed on July 20, 2011. Original Filing: 300403508.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2011

Q1 Report

In Q1, GENZYME CORPORATION had in-house lobbyists. The report was filed on April 20, 2011. Original Filing: 300379033.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2010

Q4 Report

In Q4, GENZYME CORPORATION had in-house lobbyists. The report was filed on Jan. 20, 2011. Original Filing: 300353363.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

H.R. 444, 340B Program Improvement and Integrity Act of 2009, 340B drug price expansion ESRD "Bundling Issues" and ESRD Drug Reimbursement Issues HCPCS Coding Decisions Reimbursement for Part B Drugs Administered in Hospital Out-patient Departments, Dialysis Centers and Physician OfficesPhysician Fee Schedule Payment Rates for Lab Tests Medicaid Rebates Implementation of MIPPA H.R. 1699, Patient Access to Critical Lab Test H.R. 1452, Medicare Clinical Diagnostic Laboratory Fee Schedule Modernization Act of 2009 Reimbursement /Payment Laboratory Tests H.R. 676, US National Health Care Act or the Expanded and Improved Medicare for All Act Reimbursement for Clinical Lab Tests Reimbursement for Medicare Part D Drugs P.L. 111-148, Patient Protection & Affordable Health Care Act P.L. 111-152, Health Care and Education Reconciliation Act of 2010 S. 11, To Restore the Application of the 340B Drug Discount Program to Orphan Drugs with Respect to Children's Hospitals S. Amendment (Baucus) to H.R. 4848, Small Business and Infrastructure Jobs Tax Act of 2010 (340B Provisions) H.R. 1586, Education Jobs and Medicaid Funding Bill (AMP Revisions) H.R. 4899, Supplemental Appropriations Act 2010 (AMP Revisions) H.R.5712, Veterans', Seniors', and Children's Health Technical Corrections Act of 2010 (340B Orphan Drug Children's Hospitals Provision) Health Care Reform Implementation Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2010

Q3 Report

In Q3, GENZYME CORPORATION had in-house lobbyists. The report was filed on Oct. 20, 2010. Original Filing: 300328013.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2010

Q2 Report

In Q2, GENZYME CORPORATION had in-house lobbyists. The report was filed on July 20, 2010. Original Filing: 300302227.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

H.R. 444, 340B Program Improvement and Integrity Act of 2009, 340B drug price expansion ESRD "Bundling Issues" and ESRD Drug Reimbursement Issues HCPCS Coding Decisions Reimbursement for Part B Drugs Administered in Hospital Out-patient Departments, Dialysis Centers and Physician OfficesPhysician Fee Schedule Payment Rates for Lab Tests Medicaid Rebates Implementation of MIPPA H.R. 1699, Patient Access to Critical Lab Test H.R. 1452, Medicare Clinical Diagnostic Laboratory Fee Schedule Modernization Act of 2009 Reimbursement /Payment Laboratory Tests H.R. 676, US National Health Care Act or the Expanded and Improved Medicare for All Act Reimbursement for Clinical Lab Tests Reimbursement for Medicare Part D Drugs H.R. 3962, Preservation of Access to Care for Medicare Beneficiaries and Pension Relief Act of 2010 H.R. 3590, Patient Protection & Affordable Health Care Act H.R. 4872, Health Care and Education Reconciliation Act of 2010 H.R. 4851, Continuing Extension Act of 2010 H.R. 4213, American Jobs and Closing Tax Loopholes Act of 2010 H.R. 2847, Hiring Incentives to Restore Employment Act Health Care Reform Implementation Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2010

Q1 Report

In Q1, GENZYME CORPORATION had in-house lobbyists. The report was filed on April 20, 2010. Original Filing: 300274852.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

H.R. 444, 340B Program Improvement and Integrity Act of 2009, 340B drug price expansion H.R. 1832, Medicare Prescription Drug Affordability Act of 2009 S. 266, Medicare Prescription Drug Gap Reduction Act of 2009 S. 301, Physician Payments Sunshine Act of 2009ESRD "bundling issues" and ESRD drug reimbursement issues HCPCS coding decisions Reimbursement for Part B drugs administered in hospital out patient departments, dialysis centers and physician offices Physician fee schedule payment rates for lab tests Medicaid rebates Implementation of MIPPA H.R. 1699, Patient Access to Critical Lab Test H.R. 1452, Medicare Clinical Diagnostic Laboratory Fee Schedule Modernization Act of 2009 Reimbursement /Payment laboratory tests H.R. 676, US National Health Care Act or the Expanded and Improved Medicare for All Act S. 1110, Medicare Payment Advisory Commission Reform Act of 2009 H.R. 2502, Comparative Effectiveness Research Act of 2009 S. 1213, Patient Centered Outcomes Research Act of 2009 H.R. 3200, America's Affordable Health Choices Act of 2009 Reimbursement for Clinical Lab Tests Reimbursement for Medicare Part D Drugs S. 1679, America's Affordable Health Choices Act of 2009 H.R. 3962, Affordable Health Care for Americans Act H.R. 3590, Patient Protection & Affordable Health Care Act H.R. 4872, Health Care and Education Reconciliation Act of 2010 H.R. 4851, Continuing Extension Act of 2010 H.R. 4213, Workers, State, and Business Relief Act of 2010 H.R. 2847, Hiring Incentives to Restore Employment Act Extension of the TC Grandfather Clause

Agencies Lobbied

Type of Issue

Lobbying Issues

H.R. 1548, Pathway for Biosimilars Act of 2009 H.R. 1427, Promoting Innovation and Access to Life-Saving Medicines Act S. 726, Promoting Innovation and Access to Life-Saving Medicines Act S. 301, Physician Payments Sunshine Act of 2009H.R. 3156, Neglected Disease Tax Credit Bill H.R. 1298, Pharmaceutical Market Access & Drug Safety Act of 2009" - Importation. S.525, "Pharmaceutical Market Access & Drug Safety Act of 2009" - Importation H.R. 759, Food and Drug Administration Globalization Act of 2009 S. 1679, America's Affordable Health Choices Act of 2009 H.R. 3962, Affordable Health Care for Americans Act H.R. 3590, Patient Protection & Affordable Health Care Act Treatment of Orphan Drugs Under 340B Expansion H.R. 4872, Health Care and Education Reconciliation Act of 2010

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2009

Q4 Report

In Q4, GENZYME CORPORATION had in-house lobbyists. The report was filed on Jan. 20, 2010. Original Filing: 300246824.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

H.R. 444, 340B Program Improvement and Integrity Act of 2009, 340B drug price expansion H.R. 1832, Medicare Prescription Drug Affordability Act of 2009 S. 266, Medicare Prescription Drug Gap Reduction Act of 2009 S. 301, Physician Payments Sunshine Act of 2009ESRD "bundling issues" and ESRD drug reimbursement issues HCPCS coding decisions Reimbursement for Part B Drugs administered in hospital out patient departments, dialysis centers and physician officers Physicians fee schedule payment rates for lab tests Medicaid rebates Implementation of MIPPA H.R. 1699 Patient Access to Critical Lab Test H.R. 1452 Medicare Clinical Diagnostic Laboratory Fee Schedule Modernization Act of 2009 Reimbursement /Payment laboratory tests H.R. 676 - US National Health Care Act or the Expanded and Improved Medicare for All Act House Tri-Committee Health Reform Bill Senate Finance Health Reform Bill S. 1110, Medicare Payment Advisory Commission Reform Act of 2009 H.R. 2502, Comparative Effectiveness Research Act of 2009 S. 1213, Patient Centered Outcomes Research Act of 2009 H.R. 3200, America's Affordable Health Choices Act of 2009 Reimbursement for Clinical Lab Tests Reimbursement for Medicare Part D Drugs S. 1679, America's Affordable Health Choices Act of 2009 H.R. 3962, Affordable Health Care for Americans Act H.R. 3590, Patient Protection & Affordable Health Care Act

Agencies Lobbied

Type of Issue

Lobbying Issues

H.R. 1548, Pathway for Biosimilars Act of 2009 H.R. 1427, Promoting Innovation and Access to Life-Saving Medicines Act S. 726 Promoting Innovation and Access to Life-Saving Medicines Act S. 301 Physician Payments Sunshine Act of 2009H.R. 3156, Neglected Disease Tax Credit Bill H.R. 1298, Pharmaceutical Market Access & Drug Safety Act of 2009" - Importation. S.525, "Pharmaceutical Market Access & Drug Safety Act of 2009" - Importation H.R. 759, Food and Drug Administration Globalization Act of 2009 S. 1679, America's Affordable Health Choices Act of 2009 House Tri-Caucus Health Reform Bill H.R. 3962, Affordable Health Care for Americans Act H.R. 3590, Patient Protection & Affordable Health Care Act Treatment of Orphan Drugs Under 340B Expansion

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2009

Q3 Report

In Q3, GENZYME CORPORATION had in-house lobbyists. The report was filed on Oct. 20, 2009. Original Filing: 300220678.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

H.R. 444, 340B Program Improvement and Integrity Act of 2009, 340B drug price expansion H.R. 1832, Medicare Prescription Drug Affordability Act of 2009 S. 266, Medicare Prescription Drug Gap Reduction Act of 2009 S. 301, Physician Payments Sunshine Act of 2009Comparative Effectiveness ESRD "bundling issues" and ESRD drug reimbursement issues Medicare prescription drug benefit CPT Coding decisions and HCPCS coding decisions Reimbursement for Part B Drugs administered in hospital out patient departments, dialysis centers and physician officers Physicians fee schedule payment rates for lab tests Medicaid rebates MIPPA Technical Corrections H.R. 1699 Patient Access to Critical Lab Test H.R. 1452 Medicare Clinical Diagnostic Laboratory Fee Schedule Modernization Act of 2009 Reimbursement /Payment laboratory tests S. 275 Children's Health Insurance Program Reauthorization Act of 2009 H.R. 2 Children's Health Insurance Program Reauthorization Act of 2009 H.R. 676 - US National Health Care Act or the Expanded and Improved Medicare for All Act Least Costly Alternative (LCA) policy for viscosupplements Kennedy Health Reform Bill House Tri-Committee Health Reform Bill Senate Finance Health Reform Bill S. 1110, Medicare Payment Advisory Commission Reform Act of 2009 H.R. 2502, Comparative Effectiveness Research Act of 2009 S. 1213, Patient Centered Outcomes Research Act of 2009 H.R. 3200, America's Affordable Health Choices Act of 2009 Reimbursement for Clinical Lab Tests Reimbursement for Medicare Part D Drugs

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2009

Q2 Report

In Q2, GENZYME CORPORATION had in-house lobbyists. The report was filed on July 20, 2009. Original Filing: 300192953.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

H.R. 444, 340B Program Improvement and Integrity Act of 2009, 340B drug price expansion H.R. 1832, Medicare Prescription Drug Affordability Act of 2009 S. 266, Medicare Prescription Drug Gap Reduction Act of 2009 S. 301, Physician Payments Sunshine Act of 2009Comparative Effectiveness ESRD "bundling issues" and ESRD drug reimbursement issues Medicare prescription drug benefit CPT Coding decisions and HCPCS coding decisions Reimbursement for Part B Drugs administered in hospital out patient departments, dialysis centers and physician officers Physicians fee schedule payment rates for lab tests Medicaid rebates MIPPA Technical Corrections H.R. 1699 Patient Access to Critical Lab Test H.R. 1452 Medicare Clinical Diagnostic Laboratory Fee Schedule Modernization Act of 2009 Reimbursement /Payment laboratory tests S. 275 Children's Health Insurance Program Reauthorization Act of 2009 H.R. 2 Children's Health Insurance Program Reauthorization Act of 2009 H.R. 676 - US National Health Care Act or the Expanded and Improved Medicare for All Act Least Costly Alternative (LCA) policy for viscosupplements Kennedy Health Reform Bill House Tri-Committee Health Reform Bill Senate Finance Health Reform Bill S. 1110, Medicare Payment Advisory Commission Reform Act of 2009 H.R. 2502, Comparative Effectiveness Research Act of 2009 S. 1213, Patient Centered Outcomes Research Act of 2009

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2009

Q1 Report

In Q1, GENZYME CORPORATION had in-house lobbyists. The report was filed on April 20, 2009. Original Filing: 300163619.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

H.R. 444, 340B Program Improvement and Integrity Act of 2009, 340B drug price expansion H.R. 1832 Medicare Prescription Drug Affordability Act of 2009 S. 266 Medicare Prescription Drug Gap Reduction Act of 2009 S. 301, Physician Payments Sunshine Act of 2009Comparative Effectiveness ESRD "bundling issues" and ESRD drug reimbursement issues Medicare prescription drug benefit CPT Coding decisions and HCPCS coding decisions Reimbursement for Part B Drugs administered in hospital out patient departments, dialysis centers and physician officers Physicians fee schedule payment rates for lab tests. Medicaid rebates MIPPA Technical Corrections H.R. 1699 Patient Access to Critical Lab Test H.R. 1452 Medicare Clinical Diagnostic Laboratory Fee Schedule Modernization Act of 2009 Reimbursement /Payment laboratory tests S. 275 Children's Health Insurance Program Reauthorization Act of 2009 H.R. 2 Children's Health Insurance Program Reauthorization Act of 2009 H.R. 676 - US National Health Care Act or the Expanded and Improved Medicare for All Act Least Costly Alternative (LCA) policy for viscosupplements

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2008

Q4 Report

In Q4, GENZYME CORPORATION had in-house lobbyists. The report was filed on Jan. 21, 2009. Original Filing: 300132125.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

H.R. 2606, 340B Program Improvement and Integrity Act of 2007, 340B drug price expansion H.R. 3162, Children's Health and Medicare Protection Act of 2007 H.R. 4, Medicare Prescription Drug Price Negotiation Act, Medicare noninterference provisions H.R. 5480 Medicare Funding Warning Response Act of 2008S. 1376, 340B Program Improvement and Integrity Act of 2007, 340B Drug price expansion S. 2029, Physician Payments Sunshine Act of 2007 S. 2662, Medicare Funding Warning Response Act of 2008 S. 3, Medicare Prescription Drug Price Negotiation Act, Medicare noninterference provision Comparative Effectiveness S. 2099 "Preserving Access to Laboratory Services Act of 2007" Repeal of Competitive bidding demo ESRD "bundling issues" and ESRD drug reimbursement issues Medicare prescription drug benefit H.R. 1321 "Medicare Advanced Laboratory Diagnostic Act of 2007" S. 691/H.R. 1193 The Kidney Care Quality and Education Act CPT Coding decisions and HCPCS coding decisions Reimbursement for Part B Drugs administered in hospital out patient departments, dialysis centers and physician officers Physicians fee schedule payment rates for lab tests. Medicaid rebates H.R. 2184, The Enhanced health Care Value for All Act H.R. 6331 "Medicare Improvements for Patients and Providers Act of 2008" S. 3101, "Medicare Improvements for Patients and Providers Act of 2008" MIPPA Technical Connections H.R. 1472 Emergency Economic Stabilization Act of 2008

Agencies Lobbied

Type of Issue

Lobbying Issues

H.R. 1038, Access to Life-Saving Medicine Act, follow-on biologics H.R. 1956, Patient Protection and Innovative Biologic Medicines Act of 2007, Follow-on biologics H.R. 5629, Pathway for Biosimilars Act S. 1505, Affordable Biologics for Consumers Act of 2007, follow-on biologicsS.1695, Biologics Price Competition and Innovation Act of 2007, Follow-on Biologics S. 2029, Physician Payments Sunshine Act of 2007 S. 623, Access to Life-Saving Medicine Act, follow-on biologics Neglected Disease Issues Issues related to Drug Safety, Generic Biologics & Drug Approvals H.R. 380, "Pharmaceutical Market Access and Drug Safety Act of 2007" - Importation. S.251, Pharmaceutical Market Access & Drug Safety Act of 2007" - Importation. S.242, "Pharmaceutical Market Access & Drug Safety Act of 2007" H.R. 1561, Enhancing Drug Safety and Innovation Act of 2007 H.R. 3610 Food and Drug Import Safety Act of 2007 S. 4, Improving America's Security Act of 2007, cargo-screening provision

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2008

Q3 Report

In Q3, GENZYME CORPORATION had in-house lobbyists. The report was filed on Oct. 20, 2008. Original Filing: 300106695.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2008

Q2 Report

In Q2, GENZYME CORPORATION had in-house lobbyists. The report was filed on July 21, 2008. Original Filing: 300078961.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

H.R. 2606, 340B Program Improvement and Integrity Act of 2007, 340B drug price expansion H.R. 3162, Children's Health and Medicare Protection Act of 2007 H.R. 4, Medicare Prescription Drug Price Negotiation Act, Medicare noninterference provisions H.R. 5480m Medicare Funding Warning Response Act of 2008S. 1376, 340B Program Improvement and Integrity Act of 2007, 340B Drug price expansion S. 2029, Physician Payments Sunshine Act of 2007 S. 2662, Medicare Funding Warning Response Act of 2008 S. 3, Medicare Prescription Drug Price Negotiation Act, Medicare noninterference provision Comparative Effectiveness S. 2099 "Preserving Access to Laboratory Services Act of 2007" Repeal of competitive bidding demo ESRD "bundling issues" and ESRD drug reimbursement issues Medicare prescription drug benefit H.R. 1321 "Medicare Advanced Laboratory Diagnostic Act of 2007" S.2404 "The Medicare Advanced Laboratory Diagnostic Act of 2007" S. 691/H.R. 1193 The Kidney Care Quality and Education Act CPT Coding decisions and HCPCS coding decisions Reimbursement for Part B Drugs administered in hospital outpatient departments, dialysis centers and physician officers Physicians fee schedule payment rates for lab tests. Medicaid rebates H.R. 2184, the Enhanced health Care Value for All Act H.R. 6331 "Medicare Improvements for Patients and Providers Act of 2008" S.3101, "Medicare Improvements for Patients and Providers Act of 2008"

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2008

Q1 Report

In Q1, GENZYME CORPORATION had in-house lobbyists. The report was filed on April 17, 2008. Original Filing: 300041615.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

H.R. 2606, 340B Program Improvement and Integrity Act of 2007, 340 B drug price expansion H.R. 3162, Children's Health and Medicare Protection Act of 2007 H.R. 4, Medicare Prescription Drug Price Negotiation Act, Medicare noninterference provisions H.R. 5480, Medicare Funding Warning Response Act of 2008S. 1376, 340B Program Improvement and Integrity Act of 2007, 340 B Drug price expansion S. 2029, Physician Payments Sunshine Act of 2007 S. 2662, Medicare Funding Warning Response Act of 2008 S. 3, Medicare Prescription Drug Price Negotiation Act, Medicare noninterference provision Comparative Effectiveness S. 2099 "Preserving Access to Laboratory Services Act of 2007" Repeal of competitive bidding demo Bundling payment system for dialysis centers Medicare prescription drug benefit H.R. 1321 "Medicare Advanced Laboratory Diagnostics Act of 2007" S.2404 "The Medicare Advanced Laboratory Diagnostic Act of 2007" S.691/H.R. 1193 The Kidney Care Quality and Education Act CPT Coding decisions and HCPCS coding decisions Reimbursement for Part B Drugs administered in hospital outpatient departments, dialysis centers and physician officers. Physicians fee schedule payment rates for lab tests. Medicaid rebates H.R. 2184, the Enhanced Health Care Value for All Act

Agencies Lobbied

Type of Issue

Lobbying Issues

H.R. 1038, Access to Life-Saving Medicine Act, follow-on biologics H.R. 1956, Patient Protection and Innovative Biologic Medicines Act of 2007, follow-on biologics H.R. 5629, Pathway for Biosimilars ActS. 1505, Affordable Biologics for Consumers Act of 2007, follow-on biologics S. 1695, Biologics Price Competition and Innovation Act of 2007, Follow-on Biologics S. 2029, Physician Payments Sunshine Act of 2007 S. 623, Access to Life-Saving Medicine Act, follow-on biologics Neglected Disease Issues Issues related to Drug Safety, Generic Biologics & Drug Approvals H.R. 380, "Pharmaceutical Market Access and Drug Safety act of 2007" - Importation. S.251, Pharmaceutical Market Access & Drug Safety Act of 2007" - Importation. S.242, "Pharmaceutical Market Access & Drug Safety Act of 2007" H.R. 1561, Enhancing Drug Safety and Innovation Act of 2007

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Source: Clerk of the U.S. House of Representatives and Secretary of the Senate

Legislators

Bills

Statements

Lobbying

Travel

Lobbyists

Disclosures Filed